Continuous subcutaneous foslevodopa/foscarbidopa infusion therapy leads to a sustained reduction in dyskinesias in Parkinson’s disease
Objective: To assess the longitudinal effect of continuous subcutaneous foslevodopa/foscarbidopa infusion therapy on dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) total score…Assessing the potential association of rs2298383 in ADORA2A as a predictor of Levodopa-Induced Dyskinesia in Latin American Parkinson’s Disease patients
Objective: To analyze the association between ADORA2A-rs2298383 and levodopa induced dyskinesias (LID) in a cohort of Latin American Parkinson’s disease patients. Background: Previous evidence has…Effects of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy on Motor Complications in Parkinson’s Disease
Objective: To evaluate the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) treatment on motor complications in Parkinson’s disease (PD). Background: Motor…Does COMT Play a Role in Parkinson’s Disease Susceptibility Across Diverse Ancestral Populations?
Objective: To investigate the relationship between COMT genetic variants and PD risk across diverse ancestries. Background: The enzyme catechol-O-methyltransferase (COMT; OMIM:116790) plays a crucial role…The Feedback Loop: Illness Perceptions and Motor Complications in Parkinson’s
Objective: To explore the relationship between motor complications, illness perceptions and cognitive beliefs about symptoms in people with Parkinson's disease (PwP). Background: Around 50% PwP…Clinical Differences Among Parkinson’s Disease Patients Carrying GBA1 Variants in Colombia: Insights From LARGE-PD Consortium
Objective: To compare the clinical manifestations of GBA1 variants p.K198E, p.E326K, and p.N370S in Parkinson’s disease(PD) patients in Colombia. Background: GBA1 variants have been identified…Improved Decision-Making for In-Hospital Medication Management in Parkinson’s Disease
Objective: To enhance clinical decision-making in PD management by developing and validating a conformal prediction framework that forecasts Levodopa Equivalent Daily Dose (LEDD) changes with…Treatment Of Advanced Parkinson’s With Levodopa–Entacapone–Carbidopa Intestinal Gel – Impact On Dyskinesia
Objective: To evaluate the effect of long-term treatment with levodopa–entacapone–carbidopa intestinal gel (LECIG) infusion on daily time with dyskinesia in people with advanced Parkinson’s disease…Novel CUX2 Mutation Identified in Patient with Clinical Paroxysmal Nonkinesigenic Dyskinesia
Objective: In this case, we present a novel mutation in the regulatory region for CUX-2 that is associated with clinical PNKD. Background: Paroxysmal nonkinesigenic dyskinesias…Effect of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on motor fluctuations, dyskinesia, and sleep; subjective vs. PKG watch recordings.
Objective: To evaluate the impact of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa on bradykinesia, dyskinesia, and sleep quality using self-reported Hauser diaries and Parkinson’s KinetiGraph…
- 1
- 2
- 3
- …
- 44
- Next Page »